Acupuncture for improving gait disturbance in Parkinson ’s disease: A study protocol for a pilot randomized controlled trial

Conclusions This trial will evaluate clinical effects of acupuncture in PD patients, and will confirm whether acupuncture alters neurotransmitter levels and associated activities. We expect improvement in gait parameters, changes in motor and prefrontal cortex activity, and changes in neurotransmitter activity, thereby providing insight into the therapeutic mechanism of acupuncture in PD and supporting further studies of whether acupuncture may improve motor symptoms in PD.
Source: European Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research

Related Links:

Condition:   Parkinson Disease Interventions:   Drug: Pridopidine;   Drug: Placebo Sponsor:   Prilenia Therapeutics Development Ltd. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conclusions The treatment used for PD, particularly DA, is associated with the development of ICDs and related behaviors. Susceptibility to these disorders depends on the associated risk factors. ICDs can have serious personal, family, psychosocial, financial, and medical consequences. However, in contrast, artistic activities have been described in patients with PD while undergoing treatment with DA. These patients are compulsive but report a positive influence on quality of life. These findings highlight the need for a very critical approach at the moment of Dopaminergic Replacement therapy choice. Author Contributio...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
In this study, we focused primarily on the change of sensory weighting parameters when sensory conditions change. We also tested the additional hypothesis that levodopa medication would improve sensory weighting for postural control. Materials and Methods Subjects The Institutional Review Board at Oregon Health and Science University (OHSU) approved the protocol for this experiment, and all subjects gave informed consent prior to participating. Eight subjects with PD (three female) and eight healthy, age-matched controls (two female) were recruited from the Balance Disorders Laboratory database and the Parkinson’s...
Source: Frontiers in Human Neuroscience - Category: Neuroscience Source Type: research
Publication date: Available online 12 April 2019Source: Neurochemistry InternationalAuthor(s): Satarupa Deb, Banashree Chetia Phukan, Muhammed Khairujjaman Mazumder, Ankumoni Dutta, Rajib Paul, Pallab Bhattacharya, Rajat Sandhir, Anupom BorahAbstractGarcinol, the principal phytoconstituent of plants belonging to the genus, Garcinia, is known for its anti-oxidant as well as anti-inflammatory properties, which can be extended to its possible neuroprotective role. Recent reports disseminate the capacity of garcinol to influence neuronal growth and survival, alter the neurochemical status in brain, as well as regulate memory a...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
ConclusionAdjunctive therapy with ropinirole-SR or pramipexole appears to offer similar efficacy and tolerability in patients with advanced PD on the basis of this indirect comparison.FundingGSK
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
We report a man (current age: 59  years) without any underlying disease presenting with right‐hand tremor at the age of 39 years, followed by slow movement, rigidity, and postural instability. He developed motor fluctuation and levodopa‐induced dyskinesia 8 years later. At the age of 58 years, cognitive decline and visual h allucination ensued; he was institutionalized thereafter. We used multiplex ligation‐dependent probe amplification, which demonstrated no large deletions or duplications of relevant PD genes. Next, targeted sequencing panel covering 51 genes causative for PD was applied for the...
Source: Brain and Behavior - Category: Neurology Authors: Tags: REVIEW Source Type: research
Etienne Goubault, Hung P. Nguyen, Sarah Bogard, Pierre J. Blanchet, Erwan B ézard, Claude Vincent, Justyna Sarna, Oury Monchi, Christian Duval
Source: Frontiers in Neurology - Category: Neurology Source Type: research
In Parkinson's disease (PD), dyskinesia is considered a major side effect of dopamine replacement therapy. Nevertheless, many patients with dyskinesia function adequately.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Tags: Short communication Source Type: research
Authors: Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE Abstract INTRODUCTION: Levodopa-induced dyskinesia (LID) is a significant impediment to the long-term use of levodopa for Parkinson's disease (PD). Relatively few studies exist that have described safe and effective therapy for LID. There is thus a significant need for therapy that can control LID to allow for greater sustainability of levodopa therapy. Amantadine extended release (ER) is currently the only FDA-approved medication for the treatment of LID. While other medications have demonstrated efficacy in treating the motor symptoms of PD, amantadine ER is the ...
Source: Expert Review of Neurotherapeutics - Category: Neurology Tags: Expert Rev Neurother Source Type: research
CONCLUSION: Current evidence does not support the efficacy of the levetiracetam for treating LID in PD patients, however, due to the limited number of published randomized control trials (RCTs), further RCTs are required. PMID: 30868968 [PubMed - as supplied by publisher]
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research
More News: Acupuncture | Brain | Carbidopa/Levodopa | Complementary Medicine | Dyskinesia | Neurology | Parkinson's Disease | Study